Page 205 - İBG 2021 Faaliyet Raporu
P. 205
C
Control
Bevacizumab
fli1a:eGFP
SIVs
L1
E
L2
In-vivo angiogenesis inhibition after treatment with anti VEGF antibody fragments
In vivo angiogenesis inhibition after treatment with anti VEGF antibody fragments
Endüstriyel Ar-Ge Programı 197
